Pharmaceutical Merger

2/21/2014 5:17:00 AM,
     WILMINGTON, Del. - Directors are selling Cadence Pharmaceuticals too cheaply through an unfair process to Mallinckrodt, for $14 per share or $1.3 billion, a class action claims in Chancery Court. Attachment